ongoing

Randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic ischemic stroke.

Study Type

Interventional - Drug

Study Design

Randomized placebo controlled double-blind parallel group trial

NO. of Countries

25

NO. of Sites

250

Study Period

2020 - 2021

Sponsor

Bayer

Back To Top